(Q33799604)

English

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

0 references

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

Christopher H. Schmid

object named as

Christopher H Schmid

5

0 references

Deborah P.M. Symmons

object named as

Deborah Symmons

6

0 references

author name string

Johan Askling

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Kyle Fahrbach

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Beth Nordstrom

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Susan Ross

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

7 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pharmacoepidemiology and Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

119-130

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

TNF-alpha in promotion and progression of cancer

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Rheumatoid arthritis and cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FPDS.2046

21 January 2018

Identifiers

10.1002/PDS.2046

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33799604&oldid=1533792638"